北京福元医药股份有限公司股东会议事规则 第一章 总则 第一条 为规范北京福元医药股份有限公司（以下简称"公司"）行为，保障 股东的合法权益，保证股东会依法行使职权，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"）、《上 市公司治理准则》《上市公司股东会规则》等有关法律、行政法规、规范性文件 及《北京福元医药股份有限公司章程》（以下简称"《公司章程》"）的规定，制定 本规则。 第二条 公司股东会的召集、提案、通知、召开等事项适用本规则。 第三条 公司应当严格按照法律、行政法规、《公司章程》及本规则的相关规 定召开股东会，保证股东能够依法行使权利。 公司董事会应当切实履行职责，认真、按时组织股东会。公司全体董事应当 勤勉尽责，确保股东会正常召开和依法行使职权。 第四条 股东会应当在《公司法》《公司章程》和本规则规定的范围内行使职 权。 第五条 股东会分为年度股东会和临时股东会。年度股东会每年召开 1 次， 应当于上一会计年度结束后的 6 个月内举行。 临时股东会不定期召开，出现以下情形时，临时股东会应当在 2 个月内召开： （一）董事人数不足《公司章程》 ...

Core Insights - The company reported a third-quarter revenue of 887 million, representing a year-on-year decline of 0.55% [1] - The net profit for the third quarter was 107 million, showing a year-on-year decrease of 2.59% [1] - For the first three quarters, the total revenue was 2.521 billion, which is a year-on-year decline of 1.04% [1] - The net profit for the first three quarters amounted to 375 million, reflecting a year-on-year decrease of 6.39% [1]

投资者可于 2025 年 10 月 30 日（星期四）至 11 月 4 日（星期二） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 ir@foyou.com.cn 进行提问。公司将在说明会上对投资者普 遍关注的问题进行回答。 证券代码：601089 证券简称：福元医药 公告编号：临 2025-068 北京福元医药股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 北京福元医药股份有限公司（以下简称"公司"）将于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更全 面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计划 于 2025 年 11 月 5 日（星期三）10:00-11:00 举行 2025 年第三季度 业绩说明会，就投资者关心的问题进行交流。 会议召开时间：2025 ...

Core Insights - As of October 24, a total of 98 stocks in the Shanghai and Shenzhen markets have experienced net buying from major funds for five consecutive days or more [1] - The stock with the longest streak of net buying is Yibin Paper, which has seen net buying for 11 consecutive trading days [1] - Other notable stocks with significant net buying days include Juxing Technology, Laofengxiang, Kangwei Century, Tebao Biological, Daimei Co., Zhejiang Wenhu Internet, Huakang Clean, and Fuyuan Medical [1]

Core Points - Beijing Fuyuan Pharmaceutical Co., Ltd. has received the approval notice for the listing application of the chemical raw material drug Clobetasol [1][3] - The drug is indicated for the topical treatment of mild to moderate atopic dermatitis in patients aged 2 years and older [2] Summary by Sections Drug Basic Information - The company has obtained the "Chemical Raw Material Drug Listing Application Approval Notice" from the National Medical Products Administration for Clobetasol [1] Other Drug Information - The technical review application for Clobetasol was accepted by the National Medical Products Administration in July 2024, and the approval notice has now been issued [1] Impact on the Company - The approval of Clobetasol will enrich the company's product line and promote sustainable, stable, and healthy development [3] - The sales performance of the drug may be influenced by national policies and market environment changes, indicating a degree of uncertainty [3]

Core Viewpoint - Fuyuan Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of the raw material drug Cliborin [2] Group 1 - The approval includes the issuance of the "Chemical Raw Material Drug Marketing Application Approval Notice" [2]

Core Viewpoint - Fuyuan Pharmaceutical (601089.SH) has received approval from the National Medical Products Administration for the raw material drug Clobetasol, which is intended for local treatment of mild to moderate atopic dermatitis in patients aged 2 and above [1] Group 1 - The approval of Clobetasol will enrich the company's product line [1] - This development is expected to promote the company's sustainable, stable, and healthy growth [1]

证券代码：601089 证券简称：福元医药 公告编号：临 2025-067 北京福元医药股份有限公司 | 药品名称 | 通用名称：克立硼罗 | | --- | --- | | | 英文名/拉丁名：Crisaborole | | 通知书编号 | 2025YS00932 | | 登记号 | Y20240000682 | | 有效期 | 24个月 | | 包装规格 | 1.0kg/袋，1袋/桶；2.0kg/袋，1袋/桶；5.0kg/袋， | | | 1袋/桶；10.0kg/袋，1袋/桶。 | | 申请事项 | 境内生产化学原料药上市申请 | | 审批结论 | 根据《中华人民共和国药品管理法》及有关规 | | | 定，经审查，本品符合药品注册的有关要求， | | | 批准注册。质量标准、标签及生产工艺照所附 | | | 执行。 | | 生产企业 | 名称：北京福元医药股份有限公司 | | | 地址：河北省沧州市临港经济技术开发区华佗 | | | 路5号 | 一、药品基本情况 通知书有效期 至2030年10月21日 关于获得化学原料药上市申请批准通知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误 ...

Core Viewpoint - Fuyuan Pharmaceutical (601089) has received approval from the National Medical Products Administration for the marketing authorization of Clobetasol Propionate raw material, which is intended for the topical treatment of mild to moderate atopic dermatitis in patients aged 2 years and older [1] Company Summary - Fuyuan Pharmaceutical announced on October 24 that it has obtained the marketing authorization for Clobetasol Propionate, a significant development for the company [1] - The approval allows the company to expand its product offerings in the dermatological treatment market, specifically targeting atopic dermatitis [1] Industry Summary - The approval of Clobetasol Propionate aligns with the growing demand for effective treatments for atopic dermatitis, a common skin condition affecting a significant portion of the population [1] - The market for dermatological products is expected to see increased competition and innovation as companies seek to address various skin conditions [1]

Core Viewpoint - The approval of the raw material drug Clobetasol by the National Medical Products Administration (NMPA) enhances the company's product line, although sales may face uncertainties due to policy and market factors [1] Group 1: Regulatory Approval - The company received the approval notice for Clobetasol raw material drug with registration number Y20240000682, valid until October 21, 2030 [1] - The technical review application for this raw material drug was accepted in July 2024, currently showing status "A" on the CDE raw and auxiliary materials registration information platform [1] Group 2: Product Indication - Clobetasol is indicated for local external treatment of mild to moderate atopic dermatitis in patients aged 2 years and older [1] Group 3: Market Considerations - The approval will enrich the company's product line, but drug sales are subject to uncertainties influenced by policies and market conditions [1]